Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant...
Breathiterol Reviews, Complaints, And Side Effects: Inside The Brand’s Lung Support And Clear Breathing Claims Before Ordering